Olshan Represents Pharmacyclics in Successful $207.2 Million Public Offering
Olshan represented Pharmacyclics Inc., a NASDAQ-listed clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases, in a $207.2 million overnight public offering of 2.2 million shares of its common stock.
Capabilities
Media Contact
Marketing Contact
Mizi Mehaj
Marketing & Administrative Manager
mmehaj@olshanlaw.com
212.451.2319